Comparative Pharmacology
Head-to-head clinical analysis: LUPRON DEPOT PED KIT versus VANTAS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUPRON DEPOT PED KIT versus VANTAS.
LUPRON DEPOT-PED KIT vs VANTAS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Leuprolide acetate, a GnRH agonist, initially stimulates pituitary gonadotropin release, but chronic administration suppresses LH and FSH secretion by downregulation of GnRH receptors, leading to reduced sex steroid production.
Gonadotropin-releasing hormone (GnRH) agonist; continuous stimulation suppresses pituitary gonadotropin secretion, resulting in decreased testosterone production.
Leuprolide acetate 3.75 mg IM monthly or 11.25 mg IM every 3 months; for central precocious puberty, 7.5 mg IM monthly or 22.5 mg IM every 3 months.
10 mg subcutaneously every 24 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 3 hours following subcutaneous administration; however, due to the depot formulation, the effective half-life is extended to about 1 month, driven by the slow release from the PLGA microspheres.
Terminal elimination half-life approximately 4 weeks (28 days) due to continuous release from the implant; after implant removal, plasma concentrations decline with a half-life of about 3-4 days.
Renal (approximately 50% as unchanged drug and 50% as inactive metabolites); biliary/fecal excretion accounts for <5%
Renal: negligible. Fecal: ~100% (unchanged drug). Histrelin is not metabolized and is excreted unchanged in feces via biliary elimination.
Category C
Category C
GnRH Agonist
GnRH Agonist